Society Letters

DAA Letter on Questions from the National Clinical Care Commission

February 03, 2020

To: Linda Harris, Designated Federal Officer, National Clinical Care Commission 

"The DAA urges regulatory reforms that would allow CMS flexibility to cover innovative diabetes technologies and services, so that as new diabetes technologies and services are approved by the FDA, there is a coverage pathway in Medicare for them. Rapid advances in this space have outpaced Medicare’s existing coverage and reimbursement guidelines resulting in overly complicated or even a lack of, access processes for patients, health care professionals and suppliers."

arrow Read the Full Letter

Last Updated:
Take Action

Make Your Voice Heard

Take Action
Join us in lending your voice to our online advocacy to support our policy priorities, endocrinology, and science. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

Join us in lending your voice to our online advocacy to support our policy priorities, endocrinology, and science. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

Back to top
Short on time?

We'll come to you...

Get updates on the latest breakthroughs, clinical practice guidelines, and career development opportunities, straight to your inbox

Then take the next step: Set up your free website account and get exclusive access to even more great tools & content!